Jewett, Christina. “F.D.A. Issues Warning of Cancer Risk Linked to CAR-T Therapies.” The New York Times, The New York Times, 23 Jan. 2024, www.nytimes.com/2024/01/23/health/fda-cancer-car-t-warning.html.

This article, “F.D.A. Issues Warning of Cancer Risk Linked to CAR-T Therapies.” by Christina Jewett, sheds light on exciting information on newly past warnings from the Food and Drug Administration (FDA). The FDA ruled over companies that produce CAR-T, which is chimeric antigen receptor T-cell therapies, helping specialized cancer treatments. The companies will have to place a warning on the box acknowledging that the treatment could lead to potential risks of secondary cancers.  The box is intended to kill cancer cells rather than cause more or spread throughout the body. Studies have shown that the box has generated roughly 25 cases of secondary cancers in CAR-T therapies. 

Based on the studies in the article, it would relate to APES because CAR-T therapies could lead to better biotechnology advancements for the therapies to make a better design that will not cause or reduce the chances of getting secondary cancers from the product. It could also lead to negative factors such as risk to public health, causing an increase in cancers for the consumer. Finally, another negative factor is medical waste due to increased medical waste when disposing of improper waste management.